Email bio-eu@licor.com
LI-COR REAGENTS
IRDye® 800CW Carboxylate
Reagents for LI-COR Imaging Systems
IRDye® 800CW Carboxylate
Development and use of optical imaging agents that contain IRDye® 800CW coupled to other molecules require a control for potential effects or retention of the dye itself. The carboxylate form of IRDye 800CW is the ideal control, as it is in a non-reactive state. Note: The carboxylate dye has no reactive group and cannot be used for labeling other molecules.
(First published in: Kovar, et al. (2007) Anal. Biochem (In Press).)
Uses:
In vitro cell-based assays:
Dye-labeled targeting agents can be used in cell-based assays to evaluate binding of the labeled compound. This technique is especially useful for testing and validation of optical agents that are ultimately intended for in vivo administration. IRDye 800CW carboxylate can be used to evaluate specificity by testing for binding or other effects of the dye itself, in the absence of the targeting moiety.
In vivo imaging:
When administering an optical agent in vivo, it is important to understand the behavior and clearance of not onlythe dye-labeled imaging agent, but also the dye itself in the absence of the targeting moiety. IRDye 800CW carboxylate is the appropriate control for determining two important imaging parameters: the timing of dye clearance from the animal’s body; and specific organs or locations in the body where the dye itself may be retained for a longer period (for example, the liver or kidneys). This information allows the researcher to more accurately interpret the results of imaging experiments.
Labeling Reaction Reference
When labeling proteins or other molecules with IRDye 800CW NHS ester reactive dye, unreacted or “free” dye is removed by purification after the labeling reaction is complete. Excessive amounts of unreacted dye that persist after purification can interfere with spectrophotometric determination of a dye/protein (D/P) ratio, and result in artificially high calculated D/P values. "Free" dye may also cause increased background fluorescence in subsequent biological assays. For these reasons, it may be useful to determine the amount of unreacted dye that remains after purification.
| Extinction Coefficient |
Max. Abx. (nm) |
Max. Em. (nm) |
Properties | |
| IRDye 800CW | 300,000 | 778 | 794 | View Properties |
LI-COR Infrared Dye Successfully Completes Toxicity Studies
September 10, 2007: LINCOLN, Neb. – LI-COR® Biosciences announces successful completion of animal toxicity studies of its IRDye® 800CW infrared dye carboxylic acid using a protocol reviewed by the Food and Drug Administration. The completion of the toxicity studies is a key milestone in the development of the IRDye 800CW dye for potential clinical imaging use.
LI-COR IRDye infrared fluorescent dyes are used for protein and cellular assays, microscopy, and in vivo molecular imaging in animals for research purposes. IRDye 800CW is cited in a wide variety of published non-clinical research for labeling nucleic acids, antibodies, proteins, and peptides where there is a need for high signal, low background imaging. With an 800 nm emission wavelength, the IRDye 800CW dye is spectrally ideal for animal imaging research.
For more than 16 years scientists have used LI-COR infrared dyes for research including drug discovery, cell signaling analysis, animal imaging, and the Human Genome Project. LI-COR develops instrumentation, analysis software, and infrared reagents offering researchers a complete solution for protein analysis, genomics, and animal imaging.
“The unique characteristics of the IRDye 800CW infrared dye make it an excellent choice for molecular and small animal research,” says Jeff Harford, LI-COR product manager. “Completing the animal toxicity studies is the logical next step in the development of the IRDye 800CW infrared dye for use in the clinical setting and is critical to our preparation for future clinical investigations.”
While the IRDye 800CW dye has successfully completed toxicity studies, it has not been studied for diagnostic or therapeutic use in humans, and has not been approved by the Food and Drug Administration for this use. LI-COR is exploring options for additional studies as next steps in the Food and Drug Administration approval process leading toward clinical use.About LI-COR Biosciences: LI-COR Biosciences is a leader in the design and manufacture of instrument systems for biotechnology, plant biology and environmental research. LI-COR is a pioneer in the development of infrared fluorescence labeling and detection systems for such areas as drug discovery and DNA sequencing for genomic research. The Odyssey® and Aerius® systems offer unique infrared imaging solutions for protein analysis of Westerns, micro plate-based assays, and in vivo imaging.
Founded in 1971, the privately held company is based in Lincoln, Nebraska, with subsidiaries in Germany and the United Kingdom. LI-COR systems are used in more than 100 countries and are supported by a global network of distributors. Further information can be obtained at www.licor.com.
